MovDisordV3, Main, Exploration, bibRecord, 004A57

Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease

Identifieur interne : 004A57 ( Main/Exploration ); précédent : 004A56; suivant : 004A58

Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease

Auteurs : Alice J. Manson [Royaume-Uni] ; Elena Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-03.

RBID : ISTEX:CAAEBFD1FC37269D5775756E90774BA961B6C0CE

Descripteurs français

Pascal (Inist)
- Adulte, Antagoniste, Antiparkinsonien, Bloquant α-adrénergique, Chimiothérapie, Dyskinésie, Idazoxan, Lévodopa, Parkinson maladie, Randomisation, Récepteur imidazoline, Récepteur α2-adrénergique, Toxicité, Traitement.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Administration, Oral, Adrenergic alpha-Antagonists (adverse effects), Adrenergic alpha-Antagonists (therapeutic use), Adult, Aged, Alpha blocking agent, Antagonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Chemotherapy, Dyskinesia, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (drug therapy), Female, Humans, Idazoxan, Idazoxan (adverse effects), Idazoxan (therapeutic use), Imidazoline receptor, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson disease, Randomization, Toxicity, Treatment, Treatment Failure, α2-Adrenergic receptor.
MESH :
- chemical , adverse effects : Adrenergic alpha-Antagonists, Antiparkinson Agents, Idazoxan, Levodopa.
- chemical , therapeutic use : Adrenergic alpha-Antagonists, Antiparkinson Agents, Idazoxan, Levodopa.
- diagnosis : Dyskinesia, Drug-Induced.
- drug effects : Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Administration, Oral, Adult, Aged, Female, Humans, Male, Middle Aged, Treatment Failure.

Url:

https://api.istex.fr/document/CAAEBFD1FC37269D5775756E90774BA961B6C0CE/fulltext/pdf

DOI: 10.1002/1531-8257(200003)15:2<336::AID-MDS1023>3.0.CO;2-R

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease</title>
<author><name sortKey="Manson, Alice J" sort="Manson, Alice J" uniqKey="Manson A" first="Alice J." last="Manson">Alice J. Manson</name>
</author>
<author><name sortKey="Iakovidou, Elena" sort="Iakovidou, Elena" uniqKey="Iakovidou E" first="Elena" last="Iakovidou">Elena Iakovidou</name>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CAAEBFD1FC37269D5775756E90774BA961B6C0CE</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200003)15:2<336::AID-MDS1023>3.0.CO;2-R</idno>
<idno type="url">https://api.istex.fr/document/CAAEBFD1FC37269D5775756E90774BA961B6C0CE/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002544</idno>
<idno type="wicri:Area/Istex/Curation">002544</idno>
<idno type="wicri:Area/Istex/Checkpoint">003257</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Manson A:idazoxan:is:ineffective</idno>
<idno type="wicri:Area/Main/Merge">007354</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0177318</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C36</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000085</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002B94</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Manson A:idazoxan:is:ineffective</idno>
<idno type="wicri:Area/Main/Merge">007586</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10752589</idno>
<idno type="wicri:Area/PubMed/Corpus">004013</idno>
<idno type="wicri:Area/PubMed/Curation">004013</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003F70</idno>
<idno type="wicri:Area/Ncbi/Merge">000238</idno>
<idno type="wicri:Area/Ncbi/Curation">000238</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000238</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Manson A:idazoxan:is:ineffective</idno>
<idno type="wicri:Area/Main/Merge">007113</idno>
<idno type="wicri:Area/Main/Curation">004A57</idno>
<idno type="wicri:Area/Main/Exploration">004A57</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease</title>
<author><name sortKey="Manson, Alice J" sort="Manson, Alice J" uniqKey="Manson A" first="Alice J." last="Manson">Alice J. Manson</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Reta Lila Weston Institute of Neurological Studies, University College London, Windeyer Institute of Medical Science, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Iakovidou, Elena" sort="Iakovidou, Elena" uniqKey="Iakovidou E" first="Elena" last="Iakovidou">Elena Iakovidou</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Reta Lila Weston Institute of Neurological Studies, University College London, Windeyer Institute of Medical Science, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>The Reta Lila Weston Institute of Neurological Studies, University College London, Windeyer Institute of Medical Science, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-03">2000-03</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="336">336</biblScope>
<biblScope unit="page" to="337">337</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CAAEBFD1FC37269D5775756E90774BA961B6C0CE</idno>
<idno type="DOI">10.1002/1531-8257(200003)15:2<336::AID-MDS1023>3.0.CO;2-R</idno>
<idno type="ArticleID">MDS1023</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Adrenergic alpha-Antagonists (adverse effects)</term>
<term>Adrenergic alpha-Antagonists (therapeutic use)</term>
<term>Adult</term>
<term>Aged</term>
<term>Alpha blocking agent</term>
<term>Antagonist</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (diagnosis)</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Idazoxan</term>
<term>Idazoxan (adverse effects)</term>
<term>Idazoxan (therapeutic use)</term>
<term>Imidazoline receptor</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Randomization</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Treatment Failure</term>
<term>α2-Adrenergic receptor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic alpha-Antagonists</term>
<term>Antiparkinson Agents</term>
<term>Idazoxan</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic alpha-Antagonists</term>
<term>Antiparkinson Agents</term>
<term>Idazoxan</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Failure</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term>
<term>Antagoniste</term>
<term>Antiparkinsonien</term>
<term>Bloquant α-adrénergique</term>
<term>Chimiothérapie</term>
<term>Dyskinésie</term>
<term>Idazoxan</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Randomisation</term>
<term>Récepteur imidazoline</term>
<term>Récepteur α2-adrénergique</term>
<term>Toxicité</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Manson, Alice J" sort="Manson, Alice J" uniqKey="Manson A" first="Alice J." last="Manson">Alice J. Manson</name>
</region>
<name sortKey="Iakovidou, Elena" sort="Iakovidou, Elena" uniqKey="Iakovidou E" first="Elena" last="Iakovidou">Elena Iakovidou</name>
<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew Lees (neurologue)</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A57 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A57 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:CAAEBFD1FC37269D5775756E90774BA961B6C0CE
   |texte=   Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease

Idazoxan is ineffective for levodopa‐induced dyskinesias in Parkinson's disease

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.